ArticleApplied and environmental microbiology2026
Evaluation of beta-propiolactone and AVL-ethanol inactivation protocols for highly pathogenic avian influenza virus in allantoic fluid and cell culture.
Article in Applied and environmental microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Receptor profiling and growth assessment of influenza A virus in porcine mammary and non-mammary tissues and derived cells.Journal of virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Highly pathogenic avian influenza (HPAI) H5N1 recently expanded its host range to include dairy cattle, and since March 2024, there have been over 1,000 cases reported in the United States. This circulation in dairy cows and resulting spillover to other mammals, including 41 documented human cases, raises the risk of reassortment and development of mutations that increase virus fitness in mammalian hosts. Research on HPAI is crucial, but due to its high pathogenicity, work with live virus must be conducted in containment level 3 laboratories. Strict biosafety procedures are essential when handling virus-containing materials to ensure safety. In this report, we explore options for inactivating the virus to enable safe work in containment level 2 (CL2) laboratories, which allow for more efficient work. We tested beta-propiolactone as an inactivation agent for HPAI in cell culture media and allantoic fluid from eggs. We also tested whether Qiagen Buffer AVL with 95% ethanol could inactivate the virus in allantoic fluid. We report that 0.1% and 0.2% beta-propiolactone and Buffer AVL with ethanol were successful in completely inactivating the HPAI in cell culture media and allantoic fluid. These inactivation methods allow safe transfer of samples to CL2 laboratories and facilitate downstream application such as vaccine testing, ELISA, qPCR, and RNA sequencing.IMPORTANCEDue to the zoonotic potential of highly pathogenic avian influenza (HPAI) H5N1 virus and its highly pathogenic features, stringent biosafety measures are essential when handling virus-containing material, and work is required to be performed in containment level 3 laboratories. If any downstream work pertaining to the inactivated virus will be performed in containment level 2 laboratories, validation of complete inactivation of the virus is required, as incomplete inactivation poses a serious risk of laboratory-acquired infections and environmental release. Our study established and validated protocols of complete inactivation of HPAI H5N1 virus in allantoic fluid as well as in tissue culture medium by beta-propiolactone and AVL plus 95% ethanol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.